August 26, 2025The European Research JournalOpen Access

Comparing nivolumab response between smokers and ex-smokers in advanced non-small cell lung cancer: It is never too late to quit smoking

View Full Paper

Ask AI

Bookmark

Ex-smokers had superior objective response rates of 56% compared to 25% in current smokers, indicating a strong impact of smoking status.
The disease control rate was significantly higher in ex-smokers at 76% versus 33.3% for current smokers, with a statistical significance level of P=0.042.
Multivariate logistic regression revealed that current smokers were 3.64 times less likely to achieve an objective response to nivolumab than ex-smokers.
These findings highlight the need for clinicians to address smoking cessation among patients receiving nivolumab to improve treatment outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study shows improved treatment response in ex-smokers compared to current smokers, indicating the importance of smoking cessation.

Cite This Study

Mustafa Ersoy (2025) studied this question.

synapsesocial.com/papers/68af7f397567bf4f94ff5af2 https://doi.org/10.18621/eurj.1733954

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study shows improved treatment response in ex-smokers compared to current smokers, indicating the importance of smoking cessation.

Comparing nivolumab response between smokers and ex-smokers in advanced non-small cell lung cancer: It is never too late to quit smoking

Key Points

Discussion

Implication

Cite This Study

Comparing nivolumab response between smokers and ex-smokers in advanced non-small cell lung cancer: It is never too late to quit smoking

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading